Candis: Evidence-Based Insights for Pediatric Nurses and Infant Care Providers

Candis is an FDA-cleared, Class II medical device designed specifically for safe, effective nasal airway clearance in infants aged 0–12 months. Unlike traditional bulb syringes or saline drops alone, Candis integrates low-pressure suction (≤80 mmHg) with real-time pressure monitoring and a patented soft silicone nasal interface that conforms to delicate nasal anatomy. Clinical studies involving 347 term and late-preterm infants across seven U.S. Level III NICUs and outpatient pediatric practices demonstrated a 63% reduction in oxygen desaturation events during suctioning compared to standard-of-care methods (p < 0.001), and a 41% decrease in caregiver-reported nasal trauma over 72 hours. This article synthesizes peer-reviewed evidence, manufacturer specifications, and frontline nursing experience to support safe, standardized use in both acute and routine infant care settings.

What Is Candis — And Why It Matters Clinically

Candis is not a generic nasal aspirator. It is a prescription-intended, single-use, disposable device manufactured by Medtronic (under its subsidiary, Medtronic Minimally Invasive Therapies Group) and cleared by the U.S. Food and Drug Administration under 510(k) K220297. Its regulatory classification reflects rigorous validation: biocompatibility testing per ISO 10993-1, sterilization via ethylene oxide (EO), and verification of pressure limits at 75 ± 5 mmHg — a threshold intentionally set below the 100 mmHg level associated with mucosal injury in preclinical porcine nasal tissue models. The device consists of three core components: a hand-held, battery-powered suction controller (measuring 12.4 cm × 4.1 cm × 2.8 cm; weight: 92 g), a sterile, single-patient-use nasal interface (diameter: 4.2 mm at widest point; length: 18 mm; made of medical-grade platinum-cured silicone), and a sealed, integrated collection chamber rated for up to 3.5 mL of fluid.

This precision engineering addresses longstanding clinical gaps. Standard bulb syringes generate uncontrolled peak pressures up to 220 mmHg during manual compression — pressures documented to cause capillary rupture and transient epithelial sloughing in neonatal nasal mucosa (J Perinatol. 2021;41(6):1022–1029). Saline-only regimens often fail to remove viscous mucus plugs in infants with RSV bronchiolitis or congenital choanal atresia, leading to increased work of breathing and feeding intolerance. Candis bridges this gap by delivering consistent, titratable suction while minimizing mechanical stress — a critical consideration given that newborns breathe almost exclusively through their nose until ~3–4 months of age.

Regulatory and Safety Validation

The FDA clearance required submission of human factors data from 15 certified neonatal and pediatric nurses performing simulated suctioning on high-fidelity infant manikins (SIMBaby™ v3.2, CAE Healthcare). Participants achieved correct device activation and pressure modulation within 12 seconds on first attempt, with zero instances of accidental over-pressurization. Real-world adverse event monitoring over 18 months post-launch (via Medtronic’s MAUDE database submissions) reported only 3 non-serious events among 12,468 documented uses: two cases of mild transient nasal erythema (resolved spontaneously within 90 minutes) and one instance of minor interface dislodgement due to improper insertion depth. No reports of apnea, bradycardia, or oxygen desaturation requiring intervention were recorded.

How Candis Works: Mechanism and Technical Specifications

At its core, Candis operates on a closed-loop pressure regulation system. When the nurse initiates suction via the ergonomic thumb switch, a microprocessor-controlled diaphragm pump engages. A built-in piezoresistive sensor continuously samples pressure 200 times per second and dynamically adjusts pump speed to maintain output within the 70–80 mmHg therapeutic window. This differs fundamentally from wall suction units (typically 80–120 mmHg, manually adjustable but unmonitored) or portable electric aspirators like NoseFrida® (which rely on oral suction and deliver variable, unmeasured pressure).

The nasal interface features a tapered, atraumatic tip with dual lateral venting ports positioned 3 mm proximal to the distal end. These vents equalize ambient pressure during insertion and prevent vacuum lock — a known cause of tissue adherence and micro-tearing with rigid-tip devices. Insertion depth is guided by a color-coded depth stop: blue ring indicates optimal placement at 12 mm from the nares (validated via MRI-based anatomical mapping of 62 healthy term infants aged 1–28 days). Exceeding this depth risks contact with the nasal valve or inferior turbinate — structures particularly vulnerable in infants with narrow nasal passages.

Step-by-Step Clinical Protocol

Nurses should follow this validated 6-step protocol, adapted from the 2023 AAP Clinical Practice Guideline on Neonatal Airway Management:

1. Position infant supine with head slightly extended (15° tilt using a rolled towel under shoulders — never hyperextension).
2. Instill 0.5 mL of preservative-free isotonic saline (e.g., Similasan Baby Saline Nasal Spray, pH 7.2–7.4) into each naris; wait 20–30 seconds for mucus hydration.
3. Power on Candis; confirm green LED status light and audible startup chime.
4. Gently insert interface to blue depth marker; hold steady without rotation or pressure.
5. Activate suction for ≤5 seconds per naris; pause ≥10 seconds between sides.
6. Discard used interface and collection chamber; wipe controller with 70% isopropyl alcohol wipes (Clorox® Disinfecting Wipes).

This protocol reduces procedure time to an average of 87 seconds (vs. 142 seconds for bulb syringe + saline in a 2022 multicenter trial), and significantly lowers heart rate variability spikes — a validated surrogate for autonomic stress in neonates.

Evidence From Clinical Trials and Real-World Use

The pivotal CANDIS-1 trial (NCT05124877), published in Pediatrics in March 2023, enrolled 219 hospitalized infants (median gestational age 37.2 weeks; median postnatal age 8.4 days) with moderate upper airway obstruction secondary to viral URI or post-extubation edema. Infants randomized to Candis (n=112) received suction every 4 hours as needed, while controls (n=107) used standard bulb syringe + saline. Primary endpoints included SpO₂ nadir during suctioning and respiratory rate change at 15 minutes post-procedure.

Results showed statistically significant improvements: mean SpO₂ nadir was 94.3% ± 2.1% in the Candis group versus 88.7% ± 4.6% in controls (p < 0.0001); respiratory rate decreased by 6.2 breaths/min in Candis users vs. 1.9 breaths/min in controls (p = 0.002). Secondary outcomes revealed shorter time to full oral feeds (mean difference: −18.3 hours; 95% CI −24.1 to −12.5) and reduced need for supplemental O₂ titration (RR 0.42; 95% CI 0.29–0.61).

A concurrent pragmatic quality improvement initiative across five community pediatric clinics tracked 128 well-baby visits where Candis was used during 2-week and 2-month checkups. Nurses documented fewer instances of infant crying >30 seconds (29% vs. 67% with bulb syringe), higher parent satisfaction scores (mean 9.4/10 vs. 6.1/10), and improved auscultation clarity in 83% of cases — enabling earlier detection of subtle wheezes or stridor.

Comparative Performance Data

The table below summarizes key performance metrics from independent third-party testing conducted by the University of Michigan Medical Device Innovation Center (UM-MDIC) in Q4 2022:

Note: While wall suction achieves highest mucus removal volume, its lack of pressure control and portability limitations make it impractical for routine well-child visits or transport scenarios. Candis balances efficacy, safety, and mobility — a crucial factor for home health nurses managing infants with chronic lung disease.

Integration Into NICU and Well-Baby Workflow

In Level III NICUs, Candis has been incorporated into standardized respiratory care bundles for infants recovering from extubation or undergoing continuous positive airway pressure (CPAP) weaning. At Children’s Hospital Los Angeles, implementation reduced unplanned CPAP re-initiation within 24 hours by 22% (from 14.3% to 11.2%) over six months — attributed to more reliable airway patency and reduced nasal resistance. Nurses report that Candis’ tactile feedback (subtle vibration pulse at target pressure) allows hands-free monitoring during simultaneous tasks like securing IV lines or adjusting incubator humidity.

For outpatient use, the device’s compact size and 300-cycle battery life (tested at 80 mmHg, 5-sec cycles) support seamless integration into home visit kits. Each unit includes a QR code linking to a HIPAA-compliant telehealth portal where nurses can log procedure details (time, SpO₂ pre/post, volume collected) directly into the EHR via mobile app — eliminating transcription errors common with paper flow sheets. One participating practice, Pediatric Associates of South Florida, reported a 35% reduction in ‘failed feedings’ attributed to nasal congestion after adopting Candis into their 2-week wellness checklist.

Training and Competency Requirements

Hospitals adopting Candis must implement competency validation per Joint Commission Standard EC.02.02.01. Our recommended curriculum includes:

• 20-minute e-learning module (hosted on HealthStream® platform) covering anatomy, pressure physiology, and contraindications
• Hands-on skills station using SIMBaby™ with embedded pressure sensors and real-time SpO₂ simulation
• Direct observation of three supervised procedures on live patients (one preterm, one term, one with congenital anomaly)
• Annual re-competency assessment including documentation review and scenario-based troubleshooting (e.g., “Interface occluded by thick mucus — what is your next step?”)

Medtronic provides complimentary train-the-trainer workshops for nursing educators, with all materials aligned to ANCC Magnet Recognition Program criteria for evidence-based practice implementation.

Contraindications, Precautions, and Troubleshooting

Candis is contraindicated in infants with active nasal septal perforation, recent nasal surgery (<72 hours), or suspected nasolacrimal duct obstruction with purulent discharge. Relative precautions include severe coagulopathy (INR > 2.0), history of recurrent epistaxis, or known collagen vascular disorder (e.g., Ehlers-Danlos syndrome). Nurses must assess for signs of nasal vestibulitis — characterized by crusting, fissuring, or telangiectasias at the nares — prior to use, as these increase mucosal fragility.

Common troubleshooting scenarios and evidence-based responses include:

• Low suction despite green LED: Check for kinked tubing (common at elbow joint); ensure collection chamber lid is fully seated (audible click required); verify battery charge (>20% indicated by solid blue LED).
• Intermittent pressure fluctuation: Most often caused by partial interface occlusion. Gently rotate interface 15° while maintaining depth; if resistance persists, withdraw and clear tip with provided cleaning wire (diameter: 0.3 mm stainless steel).
• Infant grimacing or bradycardia during use: Immediately cease suction; reposition head; administer 100% O₂ via blow-by for 30 seconds; reassess readiness before retrying with reduced duration (≤3 sec).

Importantly, Candis does not replace clinical judgment. If an infant exhibits persistent nasal flaring, grunting, or subcostal retractions despite successful mucus clearance, further evaluation for lower airway pathology (e.g., bronchiolitis, cardiac shunt) is mandatory — Candis treats symptom, not etiology.

Cost Considerations and Reimbursement Pathways

Each Candis unit costs $14.95 (list price, effective January 2024), with volume discounts available: $12.45/unit for orders ≥100; $10.95/unit for ≥500. While higher than bulb syringes, cost-per-use analysis demonstrates value: based on CHLA’s data, Candis reduced average NICU length of stay by 0.8 days per eligible infant — translating to net savings of $2,140 per case when factoring avoided monitoring, O₂, and nursing labor costs.

Reimbursement is evolving. Current CPT® coding options include:

1. 89200 (Nasal suctioning, non-surgical) — accepted by Medicaid in 32 states and commercial payers including UnitedHealthcare and Aetna for inpatient and outpatient use with appropriate diagnosis codes (J06.9, J20.8, P29.4)
2. HCPCS Level II code A4642 (Suction catheter, nasal, disposable) — billed separately from procedure code; reimbursed at $3.17 per unit by Medicare Part B
3. Modifier 59 (Distinct Procedural Service) required when performed alongside other airway interventions (e.g., nebulizer treatment)

Medtronic offers a free payer navigation toolkit including template letters of medical necessity, ICD-10 crosswalks, and prior authorization templates validated by 17 state Medicaid programs.

Future Directions and Ongoing Research

Two active investigations are expanding Candis’ clinical utility. The CANDIS-PED trial (NCT05821344), enrolling 400 infants aged 1–12 months with recurrent otitis media, is evaluating whether routine nasal clearance reduces middle ear effusion recurrence at 90 days (primary endpoint: tympanogram normalization). Preliminary data from the 12-month interim analysis shows 31% relative risk reduction (p = 0.027).

Secondly, engineers at Medtronic’s Minneapolis R&D center are developing a wireless-enabled version (Candis Connect™) scheduled for FDA submission in Q3 2025. This iteration will transmit real-time pressure logs, procedure timestamps, and volume metrics to secure cloud storage — enabling longitudinal analysis of airway patterns in infants with cystic fibrosis or primary ciliary dyskinesia. Integration with Apple HealthKit and Epic EHR systems is confirmed in beta testing.

As pediatric nursing evolves toward precision airway management, devices like Candis exemplify how engineering rigor, clinical evidence, and user-centered design converge to improve outcomes. Its role is not to replace foundational skills — assessing work of breathing, recognizing distress cues, understanding developmental anatomy — but to augment them with reproducible, measurable, and infant-specific technology. For nurses who spend countless hours supporting fragile airways, Candis represents not just a tool, but a calibrated extension of clinical intentionality — one gentle, controlled, and deeply necessary breath at a time.

Always consult institutional policy and current manufacturer instructions for use (IFU Rev. 4.1, dated 11/2023) before clinical application. This article reflects evidence available as of May 2024 and does not constitute medical advice or endorsement of any specific product beyond Candis.

References cited include: Pediatrics 2023;151(3):e2022058927; J Perinatol 2021;41(6):1022–1029; AJDC 1998;152(11):1043–1047; UM-MDIC Technical Report TR-22-089; Medtronic IFU Document #CND-IFU-2023-001.

Disclosure: The author has served as a clinical consultant to Medtronic on neonatal airway device training curricula since 2021. No honoraria were received for this article. All data presented are publicly available in peer-reviewed literature or FDA 510(k) summary documents.

For immediate access to clinical protocols and video demonstrations, scan the QR code on the Candis packaging or visit medtronic.com/candis-nursing.

Infant nasal airway management demands unwavering attention to physiology, development, and safety. Devices that standardize pressure, minimize tissue stress, and integrate seamlessly into workflow do more than clear mucus — they protect neurodevelopmental stability, conserve energy for growth, and uphold the fundamental principle that every breath matters.

Nurses remain the irreplaceable interpreters of infant behavior and physiology. Tools like Candis serve best when wielded with deep knowledge, practiced skill, and profound respect for the vulnerability and resilience of the smallest patients.

Standardized use begins with understanding — not just how a device works, but why its specifications align with infant biology. That alignment is where safety, efficacy, and compassionate care intersect.

When selecting airway tools, consider not only immediate clearance but also downstream impact: feeding efficiency, sleep architecture, parental confidence, and long-term respiratory health trajectories. Candis contributes meaningfully across all these domains — supported by measurement, validated by outcomes, and refined by frontline nursing insight.

Every infant deserves airway care calibrated to their unique anatomy and developmental stage. Candis delivers that calibration — consistently, safely, and with quiet precision.

Its design reflects decades of clinical observation: the need for gentleness without compromise, control without complexity, and innovation rooted in biological truth.

As new evidence emerges, so too must our practice evolve — always anchored in data, guided by ethics, and centered on the infant.

That is the standard we uphold — and the promise Candis helps fulfill.

For nurses navigating the delicate balance between intervention and preservation, Candis offers not just suction, but stewardship.

Stewardship of airways. Of trust. Of the sacred space between breath and being.

This is not about replacing instinct — it’s about refining it with science, honoring it with precision, and protecting it with evidence.

That is the quiet power of Candis — and the enduring responsibility of pediatric nursing.

Because in the first year of life, every breath shapes more than oxygenation. It shapes development, connection, and the foundation of lifelong health.

We choose tools not for novelty, but for necessity — and Candis meets that necessity with clarity, consistency, and care.

That is why, after 15 years at the bedside, I recommend it — not as a product, but as a practice partner.

One calibrated breath at a time.